Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .
Testosterone Replacement in Androgen-Deficient Men With Ejaculatory Dysfunction: A Randomized Controlled Trial.
CONTEXT Low T levels have been associated with  ejaculatory dysfunction ( EjD ) in cross-sectional studies ; however , the efficacy of T replacement in improving EjD has not been studied in a r and omized controlled trial . OBJECTIVE To evaluate the efficacy of T replacement in and rogen-deficient men with EjD. DESIGN A multicenter , double-blind , r and omized , placebo-controlled , 16-week trial with T solution 2 % versus placebo . SETTING Medical centers in the United States , Canada , and Mexico . PATIENTS OR OTHER PARTICIPANTS Seventy-six men with one or more EjD symptoms , including delayed ejaculation , anejaculation , reduced ejaculate volume , and /or reduced force of ejaculation , and two total T levels < 300 ng/dL ( < 10.41 nmol/L ) measured with liquid chromatography t and em mass spectrometry . INTERVENTIONS Sixty milligrams of T solution 2 % or placebo applied to the axillae for 16 weeks . MAIN OUTCOME MEASURES The primary outcome was a change in the score of the three-item Male Sexual Health Question naire-Ejaculatory Dysfunction-Short Form ( MSHQ-EjD-SF ) ; secondary outcomes included measured ejaculate volume , scores of the bother/satisfaction item of the MSHQ-EjD-SF , the orgasmic function domain of the International Index of Erectile Function Question naire , and the sexual activity log . RESULTS Seventy-six participants were r and omized ; 66 completed the study . Baseline demographic and clinical characteristics were comparable between the treatment arms . T replacement improved the MSHQ-EjD-SF score ( mean score change , + 3.1 ) ; however , this effect was not statistically different from placebo ( mean score change , + 2.5 ; P = .596 ) . No differences were seen in any of the secondary outcomes or frequency of adverse events . CONCLUSION T replacement was not associated with significant improvement in EjD in and rogen-deficient men
Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .